Abstract:
Objective To study the clinicopathologic features and prognosis of breast neuroendocrine carcinoma (NEC).
Methods Thirty-two breast NEC patients were admitted between January 2003 and July 2010 to Tianjin Medical University Cancer Institute and Hospital. Their clinicopathologic data, treatment, and prognosis were retrospectively analyzed.
Results All of the 32 patients were females aged 36 years to 76 years (mean of 58.3 years), all 32 carcinomas were palpable, painless, and detected by the patients themselves. All cases were pathologically diagnosed as NEC. The immunohistochemical results showed that the positive rates for synaptophysin, NSE, and chromogranin A were 54.5% (6/11), 83.3% (20/24), and 93.75% (30/32), respectively. Twenty-seven cases were positive for ER, 22 for PR, 3 for C-erbB-2, and 6 for P53. All patients survived and were followed up for 7 to 91 months (mean of 30 months) except for one who died because of systemic multiple metastases. A positive correlation was observed between ER and PR (P < 0.01), and the positive rates for ER and PR were quite high. Moreover, both ER and PR were negatively correlated with P53 (P < 0.01 andP < 0.05, respectively) and had low positive expression. A significant difference was observed between the breast NEC simplex and complex in TNM staging (P < 0.05). All of the 13 cases of breast NEC complex had high TNM staging, whereas none of the 19 cases of breast NEC simplex had high TNM staging.
Conclusion Breast NEC is a rare and distinct category with different histological subtypes. The diagnosis of this disease should depend on the neuroendocrine markers detected by immunohistochemistry. The combined treatment is valuable for improving the overall and disease-free survival rates. Breast NEC is mostly ER and/or PR dependent and can be treated with endocrine therapy. Breast NEC simplex has relatively low TNM staging and will not easily transfer to the lymph nodes, indicating a good prognosis. Larger samples and longer follow-up periods are needed to investigate the biological characteristics and prognosis of NEC.